ArticlePloS one2016
Estrogen and Androgen Hormone Levels Modulate the Expression of PIWI Interacting RNA in Prostate and Breast Cancer.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Pooled it
- Therapeutic potential of 4-OH-coumarin in neuroblastoma: cellular, molecular, and epigenetic insights.Molecular biology research communications · 2026Article
- piR-37524 Overexpression in Colorectal Cancer: A Potential Diagnostic Bio-Marker and Therapeutic Target.Oncology research · 2026Article
- piR-RCC Suppresses Renal Cell Carcinoma Progression by Facilitating YBX-1 Cytoplasm Localization.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- The Role of PIWI-Interacting RNA in Urologic Carcinoma and Its Clinical Implications.Cancer reports (Hoboken, N.J.) · 2025Review
- Targeting Regulatory Noncoding RNAs in Human Cancer: The State of the Art in Clinical Trials.Pharmaceutics · 2025Review
- piR-823 tale as emerging cancer-hallmark molecular marker in different cancer types: a step-toward ncRNA-precision.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Non-coding RNAs as novel biomarkers and therapeutic targets in breast cancer.Oncology reviews · 2025Review
- piRNAs and PIWI proteins as potential biomarkers in Breast cancer.Molecular biology reports · 2022Review
- piR-823 inhibits cell apoptosis via modulating mitophagy by binding to PINK1 in colorectal cancer.Cell death & disease · 2022Article
- Emerging roles and potential application of PIWI-interacting RNA in urological tumors.Frontiers in endocrinology · 2022Review
- PIWI interacting RNAs perspectives: a new avenues in future cancer investigations.Bioengineered · 2021Review
- PIWI-interacting RNAs: Mitochondria-based biogenesis and functions in cancer.Genes & diseases · 2021Review
- Development of omics biomarkers for estrogen exposure using mRNA, miRNA and piRNAs.Aquatic toxicology (Amsterdam, Netherlands) · 2021Article
- piRNA-823 Is Involved in Cancer Stem Cell Regulation Through Altering DNA Methylation in Association With Luminal Breast Cancer.Frontiers in cell and developmental biology · 2021Article
- Piwi-Interacting RNAs: A New Class of Regulator in Human Breast Cancer.Frontiers in oncology · 2021Review
- The emerging role of small non-coding RNA in renal cell carcinoma.Translational oncology · 2021Review
- A Comprehensive Molecular and Clinical Analysis of the piRNA Pathway Genes in Ovarian Cancer.Cancers · 2020Article
- The emerging roles of PIWI-interacting RNA in human cancers.Cancer management and research · 2019Review
- Piwi-interacting RNAs (piRNAs) and cancer: Emerging biological concepts and potential clinical implications.Biochimica et biophysica acta. Reviews on cancer · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PIWI interacting RNAs (piRNAs), a member of non-coding RNA, originate from intergenic repetitive regions of the genome. piRNA expressions increase in various cancers and it is thought that this increase could be caused by hormones. We aimed to determine the effects of hormones on piRNA expression in breast and prostate cancer. High viability and a decrease in adhesion were observed at the concentrations of the highest proliferation. Furthermore, an increase in adhesion was also observed in MDA-MB-231 cells. After hormone treatment, while piR-651 expression had increased both breast and prostate cancer cell lines, piR-823 expressions increased in prostate cancer cell lines and only in the breast cancer cell line which was malignant. Thus, it was determined that piR-823 might show different expressions in different type of cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.